Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Net Cash Flow (2016 - 2025)

China Pharma Holdings' Net Cash Flow history spans 16 years, with the latest figure at -$4630.0 for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 83.7% year-over-year to -$4630.0; the TTM value through Dec 2025 reached -$361278.0, up 48.64%, while the annual FY2025 figure was -$361278.0, 50.62% up from the prior year.
  • Net Cash Flow reached -$4630.0 in Q4 2025 per CPHI's latest filing, up from -$399799.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $4.4 million in Q4 2021 to a low of -$1.4 million in Q2 2022.
  • Average Net Cash Flow over 5 years is -$17973.1, with a median of -$63037.5 recorded in 2022.
  • Peak YoY movement for Net Cash Flow: skyrocketed 9298.63% in 2023, then plummeted 1194.31% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $4.4 million in 2021, then crashed by 101.36% to -$60201.0 in 2022, then skyrocketed by 105.86% to $3528.0 in 2023, then tumbled by 905.33% to -$28412.0 in 2024, then skyrocketed by 83.7% to -$4630.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Net Cash Flow are -$4630.0 (Q4 2025), -$399799.0 (Q3 2025), and $254149.0 (Q2 2025).